Publication details

Waldenströmova makroglobulinemie, klinické příznaky, přehled léčebných možností a vlastní zkušenosti s léčbou ibrutinibem

Title in English Waldenström´s macroglobulinemia, overview of clinical symptoms, and therapy and our experience with ibrutinib therapy
Authors

ADAM Zdeněk ZEMAN David POUR Luděk KREJČÍ Marta KREJČÍ Martin ŘEHÁK Zdeněk KOUKALOVÁ Renata SANDECKÁ Viera ŠTORK Martin ROMANOVÁ Gabriela ADAMOVÁ Zuzana KRÁL Zdeněk

Year of publication 2022
Type Article in Periodical
Magazine / Source Onkologie
MU Faculty or unit

Faculty of Medicine

Citation
Web https://www.onkologiecs.cz/artkey/xon-202288-0006_waldenstr_mova_makroglobulinemie_klinicke_priznaky_prehled_lecebnych_moznosti_a_vlastni_zkusenosti_s_lecbou_i.php
Doi http://dx.doi.org/10.36290/xon.2022.058
Keywords Waldenström´s macroglobulinaemia; hyperviscosity; cryoglobulinemia; bendamustin; rituximab; obinutuzumab; ibrutinib
Description Waldenström macroglobulinemia (WM) is a lymphoplasmacytic lymphoma with immunoglobulin M (IgM) monoclonal protein. Clinical features include anemia, thrombocytopenia, hepatosplenomegaly, lymphadenopathy, in advanced disease hyperviscosity, kryoglobulinemia, B-symptoms and in rare cases the disease can infiltrate CNS (Big-Neel syndrom) or lungs. Presence of IgM monoclonal protein associated with clonal lymphoplasmacytic cells in bone marrow confirms the diagnosis. The L265P mutation in MYD88 is detectable in more than 90% of patients and is found in the majority of IgM MGUS patients. Not all patients who fulfill WM criteria require therapy; these patients can be observed until symptoms develop. Standard therapy is antiCD20 antibody with combination with bendamustine or cyclophospamide and dexamethasone or antiCD20 antibody with a proteosome inhibitor. In patients with early relaps after this therpay we use ibrutinib. Purine nucleoside analogues are active but usage is declining in favor of less toxic alternatives. In the 2022 we prefere for induction rituximab and bendamustine and in case of rituximab intolerance we used obinutuzumab. Given WM‘s natural history, reduction of therapy toxicity is an important part of treatment selection.

You are running an old browser version. We recommend updating your browser to its latest version.

More info